TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36765309

Group type: EXPERIMENTAL
Intervention: Intervention components to support PWIDLH to reduce drug use and improve mental health and engagement in HIV care.
Number of subjects: 0
Study: 36765312

Group type: EXPERIMENTAL
Intervention: KopOpOuders-PTSD (treatment as usual + intervention)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Treatment as usual (control condition)
Number of subjects: 142
Study: 36765313

Group type: EXPERIMENTAL
Intervention: MINS (myocardial injury after non-cardiac surgery)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (patients without MINS)
Number of subjects: 64
Study: 36765318

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)-based regimens
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Oral arsenic trioxide (oral-ATO)-based regimens
Number of subjects: 761

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 761
Study: 36765332

Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of 4 mg Triamcinolone Acetonide (TA)
Number of subjects: 16
Study: 36765344

Group type: EXPERIMENTAL
Intervention: Mzake peer group intervention delivered by trained community volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (participants served as controls until they completed the program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Youth subsample
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adult subsample
Number of subjects: 0
Study: 36765352

Group type: EXPERIMENTAL
Intervention: Posterior muscle-preserving selective laminectomy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Posterior laminectomy with fusion
Number of subjects: 300
Study: 36765414

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Number of subjects: 12924

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support with patient education materials (CDS-E)
Number of subjects: 12924

Group type: COMPARATOR
Intervention: Standard Practice (SP)
Number of subjects: 12924
Study: 36765421

Group type: EXPERIMENTAL
Intervention: t-PA only
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Plasminogen and t-PA
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Low-dose alteplase infusion (24 h)
Number of subjects: 105
Study: 36765432

Group type: EXPERIMENTAL
Intervention: Virtual genetics navigator
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Motivational interviewing by genetic health coaches
Number of subjects: 759

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 759
Study: 36765556

Group type: EXPERIMENTAL
Intervention: Calcium electroporation treatment
Number of subjects: 9
Study: 36765709

Group type: EXPERIMENTAL
Intervention: 3D conformal radiotherapy (RT)
Number of subjects: 3875

Group type: EXPERIMENTAL
Intervention: Tumor bed boost
Number of subjects: 3875

Group type: EXPERIMENTAL
Intervention: Lymph node RT
Number of subjects: 3875

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 3875

Group type: EXPERIMENTAL
Intervention: Sentinel node surgery
Number of subjects: 3875
Study: 36765803

Group type: EXPERIMENTAL
Intervention: Surgical treatment for primary tumors of the spine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Surgical resection considered 'Enneking appropriate' (EA)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall survival analysis
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 10-year follow-up
Number of subjects: 68
Study: 36765881

Group type: EXPERIMENTAL
Intervention: Positive LAB immunohistochemistry (IHC) expression (>5% of tumor cells)
Number of subjects: 256
Study: 36765948

Group type: EXPERIMENTAL
Intervention: Stereotactic salvage radiotherapy (SSRT)
Number of subjects: 25
Study: 36767448

Group type: EXPERIMENTAL
Intervention: Morning exercise (before 09:00 a.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evening exercise (after 7:00 p.m.)
Number of subjects: 0
Study: 36769445

Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (0.5 Gy)
Number of subjects: 46
Study: 36769543

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (8 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo capsules (first 4 weeks)
Number of subjects: 25
Study: 36769752

Group type: COMPARATOR
Intervention: Pilates method plus placebo PBMT/sMF
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pilates method plus active PBMT/sMF
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Only active PBMT/sMF
Number of subjects: 33
Study: 36769813

Group type: EXPERIMENTAL
Intervention: CatBoostClassifier
Number of subjects: 6495

Group type: COMPARATOR
Intervention: Traditional logistic regression and eleven ML algorithms
Number of subjects: 6495

Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP level
Number of subjects: 6495

Group type: EXPERIMENTAL
Intervention: Risk factors identified by SHAP
Number of subjects: 6495
Study: 36769854

Group type: EXPERIMENTAL
Intervention: Hospital-acquired COVID-19 infections
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Patient care staff (especially nursing assistants)
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Staff from radiology/functional assessment units and stretcher services
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Staff working on wards with COVID-19 clusters
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Geriatric wards
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Occupational risk factors
Number of subjects: 1369
Study: 36771199

Group type: EXPERIMENTAL
Intervention: Resveratrol supplement
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 36771273

Group type: EXPERIMENTAL
Intervention: Mother's own milk supplemented with preterm donor milk (PDM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mother's own milk supplemented with term donor milk (TDM)
Number of subjects: 120
Study: 36772802

Group type: EXPERIMENTAL
Intervention: Stimulation of the Premotor Cortex
Number of subjects: 0
Study: 36772948

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Medication-free condition
Number of subjects: 25
Study: 36772985

Group type: EXPERIMENTAL
Intervention: Trauma plasma-derived exosomes (100 μg and 200 μg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trauma plasma-derived exosomes (50 μg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trauma exosomal protein (100 μg) with bone marrow stromal cells
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasma from trauma patients
Number of subjects: 30
Study: 36773001

Group type: COMPARATOR
Intervention: Pilomotor function in PD patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sympathetic skin response (SSR) in PD patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Parasympathetic neurocardiac function via heart rate variability in PD patients
Number of subjects: 38
Study: 36773038

Group type: EXPERIMENTAL
Intervention: STOP-Bang screening questionnaire
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: AF-specific refinement resulting in the BOSS-GAP score
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 206
Study: 36773112

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam 3 g every 8 h for 8-14 days
Number of subjects: 726

Group type: COMPARATOR
Intervention: Meropenem 1 g every 8 h for 8-14 days
Number of subjects: 726
Study: 36773128

Group type: EXPERIMENTAL
Intervention: 0.017 × 0.025-inch stainless-steel archwire (SSAW)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.019 × 0.025-inch stainless-steel archwire (SSAW)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.021 × 0.025-inch β-titanium archwire (TMAW)
Number of subjects: 30
Study: 36773971

Group type: EXPERIMENTAL
Intervention: Bilateral 4-quadrant laparoscopic-assisted transversus abdominis plane (BLTAP) block
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard analgesia (SA)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Unilateral laparoscopic-assisted transversus abdominis plane (ULTAP) block
Number of subjects: 160

Group type: COMPARATOR
Intervention: Local anesthetic group (bupivacaine)
Number of subjects: 160
Study: 36774099

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparator group (weight-stable participants)
Number of subjects: 31
Study: 36774101

Group type: EXPERIMENTAL
Intervention: Processed diet (Meal, Ready-to-Eat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (CON)
Number of subjects: 0
Study: 36774112

Group type: EXPERIMENTAL
Intervention: Herbs and spices at doses of 0.5, 3.3, and 6.6 g/day
Number of subjects: 54
Study: 36774120

Group type: EXPERIMENTAL
Intervention: Higher frequency of animal source food (ASF) intake
Number of subjects: 7564

Group type: EXPERIMENTAL
Intervention: Higher fish intake
Number of subjects: 7564

Group type: EXPERIMENTAL
Intervention: Any meat intake
Number of subjects: 7564

Group type: EXPERIMENTAL
Intervention: Any egg intake
Number of subjects: 7564

Group type: EXPERIMENTAL
Intervention: Any dairy intake
Number of subjects: 7564
Study: 36774155

Group type: EXPERIMENTAL
Intervention: Sebetralstat (600 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 36774205

Group type: EXPERIMENTAL
Intervention: T-wave amplitude exceeding the 95th percentile in lead III
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: T-wave amplitude exceeding the 95th percentile in lead aVR
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: T-wave amplitude exceeding the 95th percentile in lead V1
Number of subjects: 2457
Study: 36774331

Group type: EXPERIMENTAL
Intervention: EuTCV
Number of subjects: 100

Group type: COMPARATOR
Intervention: Typbar-TCV®
Number of subjects: 100
Study: 36774444

Group type: EXPERIMENTAL
Intervention: Chinese visceral adiposity index (CVAI) in ERA patients
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: High CVAI group
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Baseline CVAI
Number of subjects: 104
Study: 36774447

Group type: EXPERIMENTAL
Intervention: BC-Predict (risk stratification)
Number of subjects: 5901

Group type: COMPARATOR
Intervention: Standard NHSBSP
Number of subjects: 5901
Study: 36774462

Group type: EXPERIMENTAL
Intervention: Sarcopenia index (SI)
Number of subjects: 306
Study: 36774521

Group type: EXPERIMENTAL
Intervention: Stigma-reduction training with patient narrative videos
Number of subjects: 162

Group type: COMPARATOR
Intervention: Attention-control training without patient narratives
Number of subjects: 162
Study: 36774546

Group type: EXPERIMENTAL
Intervention: Preoperative anxiety measured using a verbal numeric anxiety score (VNS)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Extent of ovarian stimulation (number of follicles, blood estradiol, and progesterone levels)
Number of subjects: 49
Study: 36774905

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine at a dose of 6 mg/kg
Number of subjects: 30
Study: 36774933

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg IV every 2 weeks for 12 doses) plus Ipilimumab (1 mg/kg IV every 6 weeks for four doses)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Number of subjects: 816
Study: 36774935

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg, max 25 mg)
Number of subjects: 1430

Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg, max 90 mg)
Number of subjects: 1430

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1430

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1430
Study: 36774994

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab
Number of subjects: 777
Study: 36775009

Group type: EXPERIMENTAL
Intervention: Fitbit Charge 5 and daily text messages
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fitbit Charge 5 and information on PA and sleep guidelines
Number of subjects: 48
Study: 36775248

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36775296

Group type: EXPERIMENTAL
Intervention: Menstrual health and genital hygiene behaviors in adolescent girls and young women with CP
Number of subjects: 163

Group type: COMPARATOR
Intervention: Healthy women control group
Number of subjects: 163
Study: 36775313

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 23

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 23
Study: 36775643

Group type: EXPERIMENTAL
Intervention: App 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: App 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36775798

Group type: EXPERIMENTAL
Intervention: Modified Atkins diet (MAD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (nonmodified higher carbohydrate diet)
Number of subjects: 16
Study: 36775965

Group type: EXPERIMENTAL
Intervention: 10 min nap
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 30 min nap
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 60 min nap
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waking (control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 30 min to 60 min naps
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Naps (10 to 60 min)
Number of subjects: 32
Study: 36775980

Group type: EXPERIMENTAL
Intervention: Current treatment with cardioprotective antidiabetic medication
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Physician-reported factors in clinical decision-making
Number of subjects: 3700
Study: 36776086

Group type: EXPERIMENTAL
Intervention: Vestibular-ocular reflex (VOR) gains measured via video head impulse test (vHIT) in patients with PSCC-BPPV
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Slow-phase velocity (SPV) of nystagmus observed during the Dix-Hallpike maneuver in the study group
Number of subjects: 62
Study: 36776263

Group type: EXPERIMENTAL
Intervention: VA-triggered CS
Number of subjects: 769

Group type: COMPARATOR
Intervention: Non-VA-triggered CS
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Non-ischemic cardiomyopathy
Number of subjects: 769
Study: 36776416

Group type: EXPERIMENTAL
Intervention: Long-arm splinting
Number of subjects: 34

Group type: COMPARATOR
Intervention: Above-elbow casting
Number of subjects: 34
Study: 36776683

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients (n=314) with myocardial injury (n=34)
Number of subjects: 497

Group type: COMPARATOR
Intervention: COVID-19 negative patients (n=183) with myocardial injury (n=57)
Number of subjects: 497
Study: 36776716

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 300
Study: 36777399

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 72
Study: 36777426

Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 36777695

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0
Study: 36777769

Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance therapy plus best supportive care (CBSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 36778131

Group type: EXPERIMENTAL
Intervention: Combined training of biofeedback and neurofeedback
Number of subjects: 0
Study: 36778232

Group type: EXPERIMENTAL
Intervention: MAMA intervention
Number of subjects: 0
Study: 36778375

Group type: EXPERIMENTAL
Intervention: Rhythmic median nerve stimulation (MNS) at 10 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rhythmic median nerve stimulation (MNS) at 12 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Arrhythmic median nerve stimulation (MNS) at 12 Hz
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 32
Study: 36778595

Group type: EXPERIMENTAL
Intervention: Nutraceutical supplements with yeast β-glucan, prebiotics, minerals
Number of subjects: 0
Study: 36778864

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg subcutaneously every 12 hours for 3 days, then 100 mg subcutaneously once daily for 4 days) in addition to standard of care (SOC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 80
Study: 36779003

Group type: EXPERIMENTAL
Intervention: Activity monitor (Fitbit Charge 3) and custom weekly surveys
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pre-pandemic period
Number of subjects: 28
Study: 36779257

Group type: EXPERIMENTAL
Intervention: Lumateperone 42 mg
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Lumateperone 28 mg
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study: 36779325

Group type: EXPERIMENTAL
Intervention: Hodgkin lymphoma treatment
Number of subjects: 6950
Study: 36779342

Group type: EXPERIMENTAL
Intervention: Nongated cardiac computed tomography angiography (CTA)
Number of subjects: 370
Study: 36779348

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 6635
Study: 36779512

Group type: EXPERIMENTAL
Intervention: Magrolimab in combination with commonly used myeloma therapies
Number of subjects: 0
Study: 36779614

Group type: EXPERIMENTAL
Intervention: Aragonite-based osteochondral implant
Number of subjects: 251

Group type: COMPARATOR
Intervention: Arthroscopic debridement/microfractures (Control)
Number of subjects: 251
Study: 36779823

Group type: EXPERIMENTAL
Intervention: 24-hour urine collection prior to stone removal
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 24-hour urine collection after stone removal
Number of subjects: 109

Group type: COMPARATOR
Intervention: Comparison of urinary parameters before and after stone removal
Number of subjects: 109

Group type: COMPARATOR
Intervention: Percentage of patients with clinically significant changes in urinary parameters
Number of subjects: 109
Study: 36779911

Group type: EXPERIMENTAL
Intervention: Electronic health record (EHR)-based clinical decision support (CDS) tools for social risk screening and documentation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDS tools designed to support CHC providers and staff.
Number of subjects: 0
Study: 36779982

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36780014

Group type: EXPERIMENTAL
Intervention: TFNA intramedullary nail
Number of subjects: 0

Group type: COMPARATOR
Intervention: PFNA-II
Number of subjects: 0
Study: 36780092

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 430
Study: 36780107

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 222
Study: 36780114

Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control (previous treatments: RG7800, olesoxime, nusinersen, onasemnogene abeparvovec)
Number of subjects: 174
Study: 36780156

Group type: EXPERIMENTAL
Intervention: Surgery (volar lock plating, percutaneous pinning, or external fixation)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Casting
Number of subjects: 293
Study: 36780158

Group type: EXPERIMENTAL
Intervention: Telemedicine consultations
Number of subjects: 696

Group type: COMPARATOR
Intervention: Telephone consultations
Number of subjects: 696
Study: 36780161

Group type: EXPERIMENTAL
Intervention: CYP cocktail + Δ9-THC
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CYP cocktail + Δ9-THC + CBD
Number of subjects: 18

Group type: COMPARATOR
Intervention: CYP cocktail + placebo
Number of subjects: 18
Study: 36780159

Group type: EXPERIMENTAL
Intervention: SER-109 (4 capsules daily for 3 days after symptom resolution following antibiotic treatment)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: SER-109
Number of subjects: 263
Study: 36780180

Group type: EXPERIMENTAL
Intervention: 1000 IU per day of oral vitamin D3 supplementation
Number of subjects: 139

Group type: COMPARATOR
Intervention: 400 IU per day of oral vitamin D3 supplementation
Number of subjects: 139
Study: 36780210

Group type: EXPERIMENTAL
Intervention: 8-week low-sodium diet intervention with individual sessions via videoconferencing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 8-week low-sodium diet intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care for hypertension management (control group)
Number of subjects: 40
Study: 36780211

Group type: EXPERIMENTAL
Intervention: Pulsewatch system (smartwatch and smartphone app) used for continuous monitoring of AF for up to 6 weeks.
Number of subjects: 90
Study: 36780265

Group type: EXPERIMENTAL
Intervention: Effective Skills to Empower Effective Men (ESTEEM); an LGBQ-affirmative transdiagnostic cognitive behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36780377

Group type: EXPERIMENTAL
Intervention: Pulmonary function test, maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), core stability tests, lumbopelvic stability test (LST), 2-minute walk test (2MWT), Timed Up and Go test (TUG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy individuals, N=30
Number of subjects: 30
Study: 36780493

Group type: EXPERIMENTAL
Intervention: 1600mg FCZ
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 2000mg FCZ
Number of subjects: 168

Group type: COMPARATOR
Intervention: AMB
Number of subjects: 168
Study: 36780608

Group type: EXPERIMENTAL
Intervention: Nivolumab and relatlimab
Number of subjects: 518
Study: 36780610

Group type: EXPERIMENTAL
Intervention: T-DXd 5.4 mg/kg intravenously once every 3 weeks (n = 373)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Physicians' choice of chemotherapy (n = 184)
Number of subjects: 557
Study: 36780674

Group type: EXPERIMENTAL
Intervention: Sublobar resection
Number of subjects: 697

Group type: COMPARATOR
Intervention: Lobar resection
Number of subjects: 697
Study: 36780675

Group type: EXPERIMENTAL
Intervention: Difelikefalin 2 mg orally twice daily for 8 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Difelikefalin
Number of subjects: 126
Study: 36780676

Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda (single subcutaneous injection, 180 μg)
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Placebo (single injection or oral)
Number of subjects: 1951

Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda
Number of subjects: 1951